Latest Regulatory News

Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.

FMR Resources has secured GroundTruth Drilling to commence a 1,500m RC drilling campaign at its Fairfield Copper Project in New Brunswick, targeting high-grade copper-silver zones and new anomalies identified by airborne EM surveys.

Sabre Resources Ltd has identified four new uranium chargeability anomalies at its Dingo Project in the Northern Territory, expanding its exploration potential in the Ngalia Basin. The company plans to drill test these targets pending regulatory approval.

Pacific Edge reports stable test volumes in Q3 FY25 despite Medicare reimbursement uncertainties and seasonal slowdowns, while gearing up for legal action against a flawed Medicare coverage decision.

Clime Capital Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.0135 per share and setting the Dividend Reinvestment Plan (DRP) issue price at AUD 0.7824.

Silver Metal Group has finalized the sale of its Texas Project to Danola Pty Ltd, shedding significant operational costs and environmental liabilities as it refocuses its strategic priorities.

Leo Lithium Limited has announced a total distribution of 17.2 cents per share, combining a capital return and a special dividend, payable at the end of January 2025.

Latin Resources Limited has secured Supreme Court approval for its acquisition by Pilbara Minerals, setting the stage for a significant consolidation in the Australian mining sector.

Buru Energy is progressing steadily on its Rafael Project, aiming for commercial agreements in early 2025 and production by late 2027, while implementing significant cost reductions to sharpen its financial position.

Energy Transition Minerals Ltd has successfully raised A$9.35 million through a strategic share placement, bolstering its financial position to advance the Kvanefjeld Rare Earths Project in Greenland and attracting new international institutional investors.

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.

Centrex Limited has announced a $10.4 million entitlement offer to eligible shareholders, aiming to strengthen its financial position and support ongoing operations at the Ardmore phosphate mine. The offer is critical amid recent debt restructuring agreements with Aurizon and NAB.